ASH Issues New Guidelines for Individualized Myelofibrosis Management | Targeted Oncology

Tailoring JAK Inhibitor Use to Disease Risk and Symptoms

JAK inhibitors can help reduce splenomegaly and alleviate other myelofibrosis-related symptoms. However, the new recommendations distinguish between patients according to disease risk and symptom burden.

For lower-risk patients experiencing disease-related symptoms, ASH recommends considering JAK inhibitor therapy. Conversely, the guidance recommends avoiding JAK inhibitors in higher-risk patients who do not have disease-related symptoms.

These recommendations underscore the need to evaluate both risk and clinical presentation when making treatment decisions, rather than relying on disease risk alone. Symptom burden, spleen enlargement, molecular findings, and transplant eligibility are among the factors relevant to individualized care.

The recommendations also address anemia associated with myelofibrosis or JAK inhibitor treatment. Anemia can complicate disease management, and the guidance identifies its management as an area requiring attention when selecting and monitoring treatment.

Aspirin Use and Thrombotic Risk

The guidelines also address low-dose aspirin use in patients with the JAK2 V617F mutation. Myelofibrosis is associated with serious disease-related complications, including blood clots, and the recommendation provides guidance on aspirin use in this genetically defined patient population.

Evidence Gaps and Future Research

Despite the recommendations, the guidelines identify several areas in which additional evidence is needed. These include improving the ability to predict which patients will benefit from specific treatments, establishing better approaches to myelofibrosis-related anemia, and clarifying the optimal timing of transplantation.

The guidance ultimately reinforces an individualized approach that integrates molecular findings, disease risk, symptoms, treatment response, and transplant eligibility. Further research will be needed to refine treatment selection, improve anemia management, and establish when transplant consultation and intervention are most appropriate.

REFERENCES1. Stein BL, Abdallah MM, Abel GA, et al. American Society of Hematology 2026 Guidelines for the Management of Myelofibrosis in Adults. Blood Adv. Published online October 14, 2026. doi:10.1182/bloodadvances.20260216502. ASH Issues New Recommendations to Improve Myelofibrosis Care. News release. American Society of Hematology. October 14, 2026. Accessed October 14, 2026. https://tinyurl.com/ykzzvwdp‌